Targeting Cancer with ERV Vaccines
One of 3,959 projects Taiyo tracks in Denmark.
Source: EU Funding & Tenders Portal
InProTher (IPT) is developing a unique immunotherapy – BreakImmune – that effectively targets endogenous retroviruses (HERVs) to treat cancer. HERVs are not expressed in normal tissues, but are expressed in several major cancers, such as breast (88%), prostate (90%), ovarian (90%), and pancreatic (80%). Thus, HERVs can be a potential target for the immune system to destroy tumor cells. IPT technol
- Status
- Closed
- Location
- Denmark
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Targeting Cancer with ERV Vaccines
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | InProTher (IPT) is developing a unique immunotherapy – BreakImmune – that effectively targets endogenous retroviruses (HERVs) to treat cancer. HERVs are not expressed in normal tissues, but are expressed in several major cancers, such as breast (88%), prostate (90%), ovarian (90%), and pancreatic (80%). Thus, HERVs can be a potential target for the immune system to destroy tumor cells. IPT technology relies on the engineering of HERVK antigens to be used as effective cancer vaccines. The administration of BreakImmune, the mutated HERVK in Ad19/MVA viral vectors, induces both strong antibody and T-cell immune responses able to destroy cancer cells in multiple cancer types. Our first product is IPT001, a first in class vaccine against solid cancers in combination with checkpoint inhibitors. |
Location
Country | Denmark |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Article published date | 2025-12-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
